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ABSTRACT
Allogeneic hematopoietic cell transplantation (HCT) is the standard of care for pediatric patients with early
medullary relapse of acute lymphoblastic leukemia (ALL). Most patients with isolated central nervous system
(CNS) relapse have good outcomes when treated with intrathecal and systemic chemotherapy followed by irra-
diation to the neuroaxis. However, the role of HCT remains unclear for those patients with early isolated CNS
relapse (\18 months) or who had high risk disease at diagnosis. We therefore compared the HCT outcomes of
116 children treated at the University of Minnesota from 1991 to 2006 with relapsed ALL involving the CNS
alone (CNS, n 5 14), the bone marrow alone (BM, n 5 85), or both bone marrow and CNS (BM 1 CNS, n 5
17). There were no significant differences among groups in age at diagnosis or transplant, length of first com-
plete remission (CR1), remission status (CR2 versus $CR3), graft source, or preparative regimen. The inci-
dence of acute GVHD was similar between groups. Patients with isolated CNS relapse had the lowest
cumulative incidence of mortality following transplant (CNS: 0%, BM: 19%, BM1 CNS: 29%, P5 .03) and re-
lapse (CNS: 0% BM: 30%, BM1CNS: 12%, at 2 years, P5 .01) and highest leukemia-free survival (CNS: 91%,
BM: 35%, BM1CNS: 46%, P\ .01) at 5 years. Risk factors for poor survival were: T cell leukemia or BCR-ABL
gene rearrangement, history of marrow relapse, and receipt of HLA-mismatched marrow. These data support
the use of allogeneic HCT in the treatment of children with poor prognosis isolated CNS relapse.
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Current therapies incorporating intensive systemic
and central nervous system (CNS)-directed therapy
have reduced the incidence of CNS relapse to\5%
in pediatric patients with acute lymphoblastic leukemia
(ALL) [1,2]. Nonetheless, when relapse does occur, the
CNS is involved in 22% to 40% of cases [1-5]. Using
current protocols, pediatric patients with standard-
risk ALL with late CNS relapse ($18 months follow-
ing the first complete remission [CR1]) have anexpected leukemia-free survival (LFS) of approxi-
mately 70%when treated with intensive chemotherapy
and CNS irradiation [6,7]. In contrast, survival is
poorer in patients with very early CNS relapse (CR1
\18 months), or CNS relapse and high-risk factors
at diagnosis (ie, age\1 or .10 years or white blood
cell count .50,000 at diagnosis) [7]. Induction and
consolidative therapy followed by allogeneic hemato-
poietic cell transplantation (HCT) is considered by
many to be the standard of care for pediatric patients685
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agnosis. The risks and potential benefits ofHCT, how-
ever, in this subgroup of children with isolated CNS
relapse has remained unclear. Therefore, we evaluated
the transplant outcomes in patients with relapsed ALL
with and without CNS involvement.
PATIENTS AND METHODS
Patient and Transplant Characteristics
One hundred sixteen pediatric patients with re-
lapsed ALL involving either the CNS, bone marrow,
or both were treated at the University of Minnesota
between 1991 and 2006 (Table 1). All transplant pro-
tocols were approved by the University of Minnesota
institutional review board, and written, informed con-
sent was provided by either the patient or their legal
guardian(s). Methods of HLA matching, donor selec-
tion, marrow, and UCB processing and infusion, test-
ing for chimerism, infection disease prophylaxis and
cytomegalovirus monitoring, and treatment of graft-
versus-host disease (GVHD) have been described pre-
viously [8-16].
All patients were in CR at the time of HCT, and
patients were grouped according to the site of relapse
in the CR immediately prior to transplantation; iso-
lated CNS relapse (CNS, n 5 14), relapse involving
both the CNS and bone marrow (BM 1 CNS,n5 17), or bonemarrow alone (BM, n5 85). As shown
in Table 1, among the groups, there were no signifi-
cant differences in the proportion of patients who
were male or Caucasian, the median age at diagnosis
of ALL or at transplant, length of CR1, or proportion
in CR2. Forty-eight patients underwent HCT from
1991 to 1995, 39 from 1996 to 2000, and 29 from
2001 to 2006. All patients were conditioned with cy-
clophosphamide (120 mg/kg) and total-body irradia-
tion (TBI) (1320-1375 cGy) alone (n 5 69) or with
the addition of etoposide in 38 or fludarabine in 8.
Five patients with isolated CNS relapse (patients 1,
3, 5, 7, and 12) had no CNS irradiation prior to
HCT. These patients were treated with additional ir-
radiation to the brain immediately prior to the HCT
conditioning chemotherapy. Thus, patients with iso-
lated CNS relapse received a total cumulative dose of
2800 6 230 cGy to the brain and 2260 6 230 cGy to
the spinal cord. Following HCT, no patients received
intrathecal chemotherapy. There were no significant
differences among groups in year of HCT, preparative
regimen, or graft source.
The indication to proceed with HCT for the ma-
jority of patients in our study was medullary leukemic
relapse. All of the 14 patients referred forHCT for iso-
lated CNS relapse had features associated with poor
outcomes. Of the 7 who underwent HCT in CR2, 5
had high WBC at diagnosis (>50,000 cells/mL, range:Table 1. Patient and Transplant Characteristics
Site of Relapse Prior to Transplantation
Factor CNS BM 1 CNS BM P
Male 7/14 (50%) 11/17 (65%) 55/85 (65%) .58
Caucasian 12/14 (86%) 16/17 (94%) 74/85 (87%) .80
Median age at diagnosis (years, range) 3.7 (1.2-7.7) 3.7 (1.4-17.0) 4.5 (1.0-16.0) .23
Median age at transplant (years, range) 8.0 (3.2-17.3) 7.8 (3.1-17.9) 8.3 (3.5-17.9) .40
Length of CR1 (months, range) 22.8 (8.6-58.4) 34.2 (3.3-74.1) 26.9 (0.8-74.3) .80
Remission status at transplant
CR2 (n, %) 7 (50%) 14 (82%) 66 (78%) .09
CR31 (n, %)* 7 (50%) 3 (18%) 19 (22%)
Year of HCT
1991-1995 6 (43%) 6 (35%) 36 (42%) .08
1996-2000 1 (7%) 8 (47%) 30 (35%)
2001-2006 7 (50%) 3 (18%) 19 (22%)
Conditioning
CY/TBI 10 (71%) 10 (59%) 49 (58%) .76
CY/TBI/FLU 4 (29%) 7 (41%) 35 (41%)
Other 0 0 1 (1%)
Transplant
HCT Donor HLA Match
BM Related 6/6 3 (21%) 8 (47%) 27 (32%) .20
BM Related 5/6 2 (14%) 0 4 (5%)
BM Unrelated 6/6 0 1 (6%) 20 (24%)
BM Unrelated 5/6 3 (21%) 3 (18%) 15 (18%)
Cord Unrelated 6/6 1 (7%) 0 3 (4%)
Cord Unrelated 5/6 3 (21%) 4 (24%) 7 (8%)
Cord Unrelated 4/6 2 (14%) 1 (6%) 9 (11%)
BM indicates bone marrow; TBI, total-body irridiation; HCT, hematopoietic cell transplant; CY, cyclophosphamide; CR, complete remission.
*One patient in the CNS group underwent HCT in CR5.
HCT for Isolated CNS Relapse of ALL 68759-282,000), 4 had early relapse (CR1 of\18months),
and 1 had T cell disease, a risk factor for CNS relapse
[1] (Table 2). In addition, patients 6 and 7 had CNS
involvement at diagnosis. Patient #6 developed sei-
zures as a complication of intrathecal chemotherapy,
and Patient #7 had suffered a CNS relapse while re-
ceiving intrathecal triple therapy with hydrocortisone,
methotrexate, and cytarabine. The remaining 7 pa-
tients with isolated CNS relapse underwent HCT in
CR3 (n 5 6) or CR5 (n 5 1), and were considered
poor prognosis because of history of multiple relapses
of ALL.
Analysis
To compare the baseline demographics and trans-
plantation-related characteristics among the 3 groups
(CNS, BM 1 CNS, and BM), the Fisher’s exact test
was used for categoric variables including gender,
race, remission status at transplant, year of HCT,
HCT donor source, and HLA-matching. The F test
was used for continuous variables including age at
diagnosis, age at transplant, and length of CR1. Cu-
mulative incidence was used to estimate transplant-
related mortality (TRM), relapse, and incidence of
GVHD [17], and the comparison of cumulative inci-
dence was conducted by using the log-rank test [18].
The Kaplan-Meier method was used to estimate
5-year LFS and overall survival (OS), and the log-
rank test was used to compare survival among the 3
groups. Factors associated with adverse outcomes
were analyzed using Cox multiple regression models
on the OS [19].RESULTS
TRM and GVHD
TRM for pediatric patients undergoing HCT for
relapsed ALL is shown in Figure 1A. In our series,
no TRM has been observed in patients with isolated
CNS relapse. Day 100 TRM was 19% (confidence in-
terval [CI]: 11%-27%) for patients with bone marrow
relapse and 29% (CI: 8%-51%) for patients with com-
bined marrow and CNS relapse (P 5 .10 at day 100).
The cumulative incidence of mortality 2 years follow-
ing HCT was lowest for patients transplanted for iso-
lated CNS relapse (0%), compared with 34% (CI:
23%-44%) for patients with bone marrow relapse
and 35% (CI: 13%-58%) for patients with combined
marrow and CNS relapse. These data were statistically
significant (P 5 .03).
Notably, the incidence of grade II-IV acute
GVHD (aGVHD) at day 100 after transplantation
was similar between groups (CNS only, 51% [CI:
24-78], BM only, 36% [CI: 26-47], or CNS 1 BM,
18% [CI: 0-35]) (Figure 1B). Similarly, there was no
significant difference in the cumulative incidence of
severe, grade III-IV aGVHD.
Relapse, LFS, and OS
At 2 years, patients undergoing HCT for isolated
CNS relapse had the lowest incidence of relapse after
transplant (0%, P 5 .01) compared to patients with
combined bone marrow and CNS relapse (12%; CI:
0-27) and patients with marrow involvement only
(30%; CI: 20-41) (Figure 2A). One patient who under-






















1 8 282 T No 14 CNS 2 UCB Alive 0.2
2 2 5.6 B No 14 CNS 2 UCB Alive 2.4
3 4 135 B No 16 CNS 2 UCB Alive 2.1
4 2 N/A B No 22 CNS 2 MRD Alive 11.3
5 2 104 B Yes 9 CNS 2 UCB Alive 1.5
6 7 60 B Yes 28 CNS 2 URD Alive 10.3
7 3 59 B Yes 31 CNS 2 MRD Alive 3.0
8 5 N/A NOS No 19 CNS 15 CNS 3 UCB Alive 7.0
9 4 N/A B No 17 CNS 6 CNS 3 URD Alive 13.1
10 2 114 B No 26 CNS 41 CNS 3 URD Alive 3.1
11 1 101 B No 23 CNS 15 CNS 3 UCB Alive 2.4
12 4 1.2 B No 52 Marrow 22 CNS 3 URD Dead 4.8
13 6 81 B Yes 35 Marrow 14 CNS 3 URD Alive 12.4
14 5 5.6 B No 58 Marrow 42 ** 5 MRD Alive 10.2
CNS indicates central nervous system;WBC, white blood cells; CR, complete remission; HCT, hematopoietic cell transplants; MRD, matched,
related donor bone marrow transplantation; URD, unrelated donor bone marrow transplantation; UCB, umbilical cord blood transplanta-
tion; N/A, not available.
*B lineage or T lineage leukemia.
**Patient 14 had 4 relapses, involving marrow, testes, CNS, and CNS, respectively.
688 P. D. Harker-Murray et al.a late CNS relapse 2.3 years following HCT. The
probability of LFS at 5 years (Figure 2B) was highest
for patients with isolated CNS relapse (91%, CI: 51-
99, P \ .01), with no difference in LFS in patients
with marrow involvement alone or in combination
with CNS involvement (BM: 35%, CI: 25-45; BM 1
CNS: 46%, CI: 22-68). Similarly, the probability of
OS (Figure 2C) was higher for the CNS group (86%
CI: 33-98%; P\ .01) than the groups with medullary
disease (BM: 38%, CI 27-49; BM 1 CNS: 53%, CI
28-73).
Prognostic Factors Impacting Survival
In this series, 14 of 15 patients with isolated CNS
relapse survived beyond 5 years. Because of the high
rate of survival of patients transplanted for isolated
CNS relapse, independent risk factors for relapse or
mortality could not be established within this group.
We therefore combined the 3 relapse groups and cal-
culated hazard ratios using Cox multiple regression












































A Transplant Related Mortality
Grade II-IV Graft-versus-Host DiseaseB
Figure 1. Complications following HCT. (A) TRM. The cumula-
tive incidence of TRM for pediatric patients undergoing HCT for
ALL was lowest for patients with isolated CNS relapse (CNS: 0;
P 5 .03), versus patients with bone marrow relapse (BM: 19%; CI:
11%-27%) or combined marrow and CNS relapse (BM 1 CNS:
29%; CI: 8%-51%). (B) Acute GVHD. The cumulative incidence
of stage II-IV aGVHD was not significantly different between
patients with isolated CNS relapse (CNS: 51% CI: 24%-78%),
bone marrow relapse (BM: 36%; CI: 26%-47%), or combined
marrow and CNS relapse (BM 1 CNS: 18% CI: 0%-35%).poorer survival (Table 3). Neither length of CR1 (cal-
culated as a contiguous or dichotomous variable) nor
age .10 years at diagnosis (versus age 1-9.99) was as-





























































Figure 2. Outcomes following HCT. (A) Relapse. The cumulative
incidence of 2 year posttransplant relapse for pediatric patients
undergoing HCT for relapsed ALL was lowest for patients with iso-
lated CNS relapse (CNS: 0%; P5 .01) when compared with patients
with bone marrow relapse (BM: 30%; CI: 20%-41%) or combined
marrow and CNS relapse (BM 1 CNS: 12%; CI: 0%-27%). (B)
EFS. Kaplan-Meier estimates of the probability of 5-year EFS of
pediatric patients undergoing HCT for ALL were highest for
patients with isolated CNS relapse (CNS: 91% CI: 51%-99%; *P\
.01), compared with patients with bone marrow relapse (BM: 35%;
CI: 25%-45%), or combined marrow and CNS relapse (BM 1
CNS: 46%, CI: 22%-68%). (C) OS. Kaplan-Meier estimates of the
probability of 5-year OS of pediatric patients undergoing HCT for
ALL with isolated CNS relapse (CNS: 86% CI: 33%-98%), bone
marrow relapse (BM: 38%; CI: 27%-49%) or combined marrow
and CNS relapse (BM 1 CNS: 53%, CI: 28%-73%) (*P\ .01).
HCT for Isolated CNS Relapse of ALL 689Table 3. Prognostic Factors for Decreased Overall Survival Using Multivariate Cox Proportional Hazards Models
Prognostic Factor Hazard Ratio (95% CI) P
Length of CR1 (months) 1.00 (0.98-1.02) .88
Age $10 at Diagnosis (versus age 1-9.99) 1.25 (0.66-2.39) .48
Ph1 or T lineage ALL (versus B lineage) 1.96 (1.06-3.62) .03
Any Marrow Involvement (versus isolated CNS relapse) 20.52 (2.60-162.7) \.01
Unrelated mismatched marrow (versus cord or matched marrow) 4.29 (2.20-8.38) \.01
CI indicates confidence interval; ALL, acute lymphoblastic leukemia; CNS, central nervous system; CR, complete remission.with T lineage disease or the presence of the Philadel-
phia chromosome had decreased survival (hazard ratio
[HR] 1.96; CI: 1.06-3.62, P 5 .03). Although all pa-
tients were in remission at the time of HCT, patients
who had any marrow involvement during the relapse
immediately prior to HCT had worse outcomes com-
pared with patients with isolated CNS relapse (HR
20.52; CI: 2.60-162.7; P\ .01). In addition, whereas
the graft source (marrow versus UCB) did not impact
survival, patients receiving an HLA mismatched, re-
lated, or unrelated BM graft (N5 27) had poorer sur-
vival compared with patients receiving either UCB or
an HLA matched BM graft (N 5 89) (HR 4.29; 2.20-
8.38; P\ .01). Although death because of relapse was
not statistically different in themismatched group (3 of
27; 11%) versus the cord blood/matched marrow
group (24 of 89; 27%: P 5 .09), death related to
GVHD was different in these groups (10 of 27; 37%
and 8/89; 9%, respectively: P\ .01). The death rate
in regard to infection was not statistically different (5
of 27; 19% versus 7/89; 8%: P 5 .11).
DISCUSSION
Induction and consolidative therapy followed by
allogeneic HCT may be considered the standard of
care for pediatric patients with ALL suffering an early
bone marrow relapse. In contrast, the routine use of al-
logeneicHCT in children with isolated CNS relapse is
controversial. The purpose of this single institution
study was to evaluate outcomes of HCT for pediatric
patients with relapsed ALL with and without CNS in-
volvement. Patients with isolated CNS relapse had the
lowest TRM and the lowest incidence of relapse fol-
lowing transplant when compared with patients with
marrow involvement of their leukemic relapse (regard-
less of CNS status). Similarly, of the 3 treatment
groups, patients with isolated CNS relapse had the
highest 5-year LFS (91%, CI: 51%-99%) and OS
(86%, CI: 33%-98%). Importantly, all of the patients
with isolated CNS relapse had features associated
with very poor outcomes using standard therapies.
Half of the patients in this group were either high
risk by National Cancer Institute (NCI) criteria (age
.10 years or WBC .50,000 at diagnosis) or suffered
a very early CNS relapse (duration of CR1 \18
months), whereas the remainder had experienced mul-tiple relapses of their leukemia prior to transplantation
(transplant performed in CR3: n 5 6; or CR5: n 5 1).
Despite these risk factors, the very favorable outcomes
observed suggest HCT should be considered a reason-
able treatment option for pediatric patients with poor
prognosis isolated CNS relapse.
Systemic chemotherapy followed by irradiation to
the brain and spinal cord has been themainstay of ther-
apy for isolated CNS relapse of ALL. Using this ap-
proach, Pediatric Oncology Group (POG) protocols
for pediatric patients with isolated CNS relapse of
ALL include POG 9061 (accrual 1990-1993, n 5 83)
and POG 9412 (accrual 1996-2000, n 5 71) and have
yielded LFS of approximately 70% when all patient
data are pooled [6,7]. Subgroup analysis of POG
9412 revealed that patients with NCI standard risk
ALL had 4-year EFS of 806 6%, and patients treated
for late CNS relapse had 4-year EFS of 786 6% [7]. In
contrast, patients with high-risk ALL according to
NCI criteria or patients with very early relapse did sig-
nificantly worse, with an estimated 5-year LFS of 51%
6 11% and 52% 6 11%, respectively [7]. In addition,
the prognosis for patients with multiple relapses of
ALL is extremely poor. Data from the Medical Re-
search Council acute lymphoblastic leukemia trials
(UKALL X and XI) included 47 pediatric patients
whose second leukemic relapse of ALL was limited
to the CNS [20]. Therapies for these patients were het-
erogeneous, and only 10 (21%) survived with a median
follow-up of 22 months (range: 1-154). Similarly, sur-
vival in pediatric patients with bone marrow involve-
ment at second relapse (with or without disease) is
also poor, ranging from 20% to 48% despite HCT
[21-24]. Thus, patients with early isolated CNS re-
lapse, CNS relapse of high-risk ALL, or isolated
CNS involvement of multiply relapsed ALL appear
to have poor outcomes with standard therapies, and
may be best served with novel or more aggressive
approaches. Although the number of patients in the
present study is small, our outcomes for these poor
prognosis patients compare favorably with reports of
outcomes in patients with similar risk features.
No randomized controlled clinical trials have com-
pared HCT to chemotherapy and irradiation for CNS
relapse of ALL. However, since 1990, nearly 20 publi-
cations have contributed data to this topic (reviewed in
[7,25]). Studies were predominantly case series and
690 P. D. Harker-Murray et al.retrospective reviews, and therapeutic approaches
ranged from chemotherapy and craniospinal irradia-
tion to autologous and allogeneic HCT. The reported
survival in individual studies varied widely, and was
likely was reflective of small numbers of patients, and
may also reflect changes in approaches to care over
this time period. These limitations are relevant to
our study as well. Nonetheless, one of the largest stud-
ies to address this topic reported outcomes of HCT for
31 pediatric patients with isolated CNS relapse using
a conditioning regimen of TBI, cytarabine, and mel-
phalan [23]. Median age at HCT was 6.5 years (range:
3-17 years) and 16 of 31 patients had an initial CR1 of
\18 months. In this study, TRM was 13% and second
relapse of leukemia was 10%6 11%, resulting in LFS
of 77% 6 15%. Although at least half of the patients
could be considered poor prognosis based on age at di-
agnosis or time to relapse (as discussed above), the
overall survival in this study was comparable to more
recent protocols using chemotherapy and irradiation.
Importantly, the authors did not note any survival dif-
ference in patients with CR1\18 months or age $10
years. Yoshihara et al. [25] recently reported the results
of allogeneic HCT for 7 pediatric patients with iso-
lated CNS relapse of ALL and 1 with T cell non-
Hodgkin’s lymphoma. Six of the leukemia patients
were characterized as having a poor prognosis because
of NCI high-risk disease or early relapse, and all were
alive at time of publication, with only 1 patient experi-
encing an additional isolated CNS relapse.
Presymptomatic CNS therapy has reduced the rate
of relapse involving the CNS from approximately 50%
of patients to \10%. Although effective in treating
CNS leukemia, initial therapies incorporating 2400
cGy to the brain induced significant long-term neuro-
cognitive deficits, and have largely been replaced by
protocols incorporating more intensive systemic and
intrathecal chemotherapy. The patients in our series
underwent HCT over 15 years. Modifications in
CNS irradiation as presymptomatic CNS therapy
may over this time period may have resulted in inade-
quate control of CNS leukemia and been responsible
for relapses in some patients. Conversely, patients
who had not received CNS irradiation prior to relapse
(patients 1, 3, 5, 7, and 12; Table 2), might be expected
to have better response to the HCT conditioning reg-
imens that incorporated TBI and cranial boosts to the
conditioning chemotherapy. Although the high sur-
vival and small sample size of our study makes it im-
possible to quantify the relative contributions of
presymptomatic CNS-directed therapy, CNS irradia-
tion, and conditioning chemotherapy, it is likely that
CNS irradiation delivered in addition to the TBI in
the transplant regimen contributed to the favorable
survival outcomes. Patients with isolated CNS relapse
could have received CNS irradiation as part of initial
therapy, at relapse, and at transplant (TBI with orwithout cranial boosts), and the cumulative doses of ir-
radiation averaged 2800 6 230 cGy to the brain and
2260 6 230 cGy to the spinal cord. These high doses
contrast with trends in POG and Children’s Oncology
Group (COG) protocols for the treatment of isolated
CNS relapse of ALL, which, over the last 2 decades,
have increased the intensity and duration of systemic
and intrathecal chemotherapy and reduced cranial
and spinal irradiation [6,7]. For example, in POG
9061, all patients received 6 months of systemic and
intrathecal chemotherapy followed by 2400 cGy to
the brain and 1500 cGy to the spinal cord. In POG
9412, duration of chemotherapy was increased to 12
months, but irradiation was reduced to 1800 cGy
and limited to the brain only for patients with late re-
lapse (CR1 $18 months). Finally, the COG study
AALL02P2 (which enrolled patients with isolated
CNS relapse in CR2 and initial CR1\18 months) fur-
ther reduced CNS irradiation to 1200 cGy to the
whole brain. Known side effects of irradiation to the
brain and spinal cord include neurocognitive deficits,
second neoplasms, decreased growth, and impaired
cardiopulmonary, renal, and endocrine function (re-
viewed in [26-29]). Thus, although our survival data
appear very encouraging when compared with survival
outcomes from standard therapies, the patients in our
study have increased risks of developing significant
long-term, radiation-induced complications.
The remainder of the patients in our study had bone
marrow involvement at leukemic relapse. A recently
published COG and Center for International Blood
and Marrow Transplant Research (CIBMTR) study of
HLA-matched sibling HCT for pediatric patients
with BM relapse of pre-B ALL in CR2 reported
8-year LFS of 41% (CI: 31%-52%) for patients with
relapse occurring\36months fromdiagnosis tofirst re-
lapse and 60% (CI: 46%-71%) for patients with relapse
occurring.36months afterdiagnosis [30]. Inour series,
LFS for patients withmedullary relapsewas comparable
at 35% (CI: 25%-45%); however, the median duration
of CR1 in our population was only 26.9 weeks and
22%of patientswere transplanted inCR3, reflecting in-
clusion of higher risk patients. Survival in our patients
with BM and CNS relapse was 45% (CI: 22%-68%).
Previous studies have suggested superior outcomes as-
sociated with longer time to relapse for patients with
relapsed ALL involving both the marrow and CNS
compared with BM relapse alone [31,32]. In our pa-
tients, there was no statistically significant difference
in length of CR1 (in months) between these 2 groups,
and similarly, we did not detect a survival advantage in
patients with combined CNS and BM relapse.
In conclusion we have observed favorable survival
in children with relapsed ALL with isolated CNS in-
volvement despite poor prognostic features. Risk of
TRM and relapse was low, although this study could
not address long-term toxicity of transplantation and
HCT for Isolated CNS Relapse of ALL 691make comparisons to what is observed with standard
chemotherapy. In these investigations, the presence
of CNS disease did not impact survival in those with
concomitantmarrowdisease.Risk factors for decreased
survival includedTcell leukemia orBCR-ABLgene re-
arrangement, any marrow relapse, and receipt of HLA
mismatched unrelated marrow. These data support
HCT as a viable option for pediatric patients with iso-
lated CNS relapse of ALL, including those associated
with poor prognostic features.
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